Merit Financial Group LLC Buys 6,267 Shares of Boston Scientific Corporation $BSX

Merit Financial Group LLC boosted its position in Boston Scientific Corporation (NYSE:BSX) by 4.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 141,195 shares of the medical equipment provider’s stock after purchasing an additional 6,267 shares during the quarter. Merit Financial Group LLC’s holdings in Boston Scientific were worth $13,785,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of BSX. Riverwater Partners LLC raised its stake in shares of Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after acquiring an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management grew its holdings in Boston Scientific by 3.8% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after purchasing an additional 99 shares during the last quarter. Crown Wealth Group LLC increased its position in shares of Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares in the last quarter. IVC Wealth Advisors LLC boosted its position in shares of Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after purchasing an additional 102 shares in the last quarter. Finally, Rise Advisors LLC grew its stake in Boston Scientific by 13.9% during the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 103 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 93,095 shares of company stock worth $9,305,450 over the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $95.98 on Wednesday. The company has a 50 day simple moving average of $98.36 and a two-hundred day simple moving average of $101.05. The stock has a market cap of $142.28 billion, a price-to-earnings ratio of 51.32, a PEG ratio of 1.93 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

BSX has been the subject of a number of research analyst reports. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Canaccord Genuity Group decreased their price objective on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Truist Financial dropped their target price on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Leerink Partners raised their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, BTIG Research reissued a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $124.85.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.